Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits

Biochemical and Biophysical Research Communications

Volumn 483, Issue 1, 2017, Pages 425-429

  Mason, R Preston ^a,b   Sherratt, Samuel C R ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ELUCIDA RESEARCH LLC   (United States)

Author keywords

Dietary supplements; Fish oils; Lipid oxidation; Omega 3 fatty acids

Indexed keywords

COPPER; FISH OIL; LIPID; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; OXIDIZED LIPID; SATURATED FATTY ACID; UNCLASSIFIED DRUG; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID;

ARTICLE; DIETARY SUPPLEMENT; FATTY ACID ANALYSIS; FATTY ACID OXIDATION; GAS CHROMATOGRAPHY; IN VITRO STUDY; LIPID COMPOSITION; PRIORITY JOURNAL; SPECTROSCOPY; UNITED STATES; ANALYSIS; CHEMISTRY; OXIDATION REDUCTION REACTION;

DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FISH OILS; LIPIDS; OXIDATION-REDUCTION; UNITED STATES;

EID: 85008233275     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.12.127     Document Type: Article

References (43)

1. [1] Kris-Etherton, P.M., Harris, W.S., Appel, L.J., Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106 (2002), 2747–2757.
2. [2] Lovaza [package insert], GlaxoSmithKline. 2014, Research Triangle Park, NC.
3. [3] Vascepa [package insert], 2016, Amarin Pharma Inc., Bedminster, NJ.
4. [4] Hilleman, D., Smer, A., Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag. Care Jan., 2016, 46–52B.
5. [5] Zargar, A., Ito, M.K., Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal supplement Database. Metab. Syndr. Relat. Disord. 9 (2011), 255–271.
6. [6] Kleiner, A.C., Cladis, D.P., Santerre, C.R., A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. J. Sci. Food Agric. 95 (2015), 1260–1267.
7. [7] Albert, B.B., Derraik, J.G., Cameron-Smith, D., Hofman, P.L., Tumanov, S., Villas-Boas, S.G., Garg, M.L., Cutfield, W.S., Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci. Rep., 5, 2015, 7928.
8. [8] Ritter, J.C., Budge, S.M., Jovica, F., Quality analysis of commercial fish oil preparations. J. Sci. Food Agric. 93 (2013), 1935–1939.
9. [9] Jackowski, S.A., Alvi, A.Z., Mirajkar, A., Imani, Z., Gamalevych, Y., Shaikh, N.A., Jackowski, G., Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety. J. Nutr. Sci., 4, 2015, e30.
10. [10] Berliner, J.A., Watson, A.D., A role for oxidized phospholipids in atherosclerosis. N. Engl. J. Med. 353 (2005), 9–11.
11. [11] Bertelsen, M., Anggard, E.E., Carrier, M.J., Oxidative stress impairs insulin internalization in endothelial cells in vitro. Diabetologia 44 (2001), 605–613.
12. [12] Baynes, J.W., Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991), 405–412.
13. [13] Turner, R., McLean, C.H., Silvers, K.M., Are the health benefits of fish oils limited by products of oxidation?. Nutr. Res. Rev. 19 (2006), 53–62.
14. [14] Walter, M.F., Jacob, R.F., Bjork, R.E., Jeffers, B., Buch, J., Mizuno, Y., Mason, R.P., Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study. J. Am. Coll. Cardiol. 51 (2008), 1196–1202.
15. [15] Walter, M.F., Jacob, R.F., Jeffers, B., Ghadanfar, M.M., Preston, G.M., Buch, J., Mason, R.P., Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J. Am. Coll. Cardiol. 44 (2004), 1996–2002.
16. [16] Lamharzi, N., Renard, C.B., Kramer, F., Pennathur, S., Heinecke, J.W., Chait, A., Bornfeldt, K.E., Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes 53 (2004), 3217–3225.
17. [17] Libby, P., Inflammation in atherosclerosis. Nature 420 (2002), 868–874.
18. [18] Rizzo, M., Berneis, K., Low-density lipoprotein size and cardiovascular risk assessment. QJM 99 (2006), 1–14.
19. [19] Koba, S., Hirano, T., Ito, Y., Tsunoda, F., Yokota, Y., Ban, Y., Iso, Y., Suzuki, H., Katagiri, T., Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis 189 (2006), 206–214.
20. [20] de Graaf, J., Hak-Lemmers, H.L., Hectors, M.P., Demacker, P.N., Hendriks, J.C., Stalenhoef, A.F., Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11 (1991), 298–306.
21. [21] Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 (2007), 1090–1098.
22. [22] Mason, R.P., Jacob, R.F., Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochim. Biophys. Acta 1848 (2015), 502–509.
23. [23] Garcia-Hernandez, V.M., Gallar, M., Sanchez-Soriano, J., Micol, V., Roche, E., Garcia-Garcia, E., Effect of omega-3 dietary supplements with different oxidation levels in the lipidic profile of women: a randomized controlled trial. Int. J. Food Sci. Nutr. 64 (2013), 993–1000.
24. [24] Nogueira, M.S., Kessuane, M.C., Lobo Ladd, A.A., Lobo Ladd, F.V., Cogliati, B., Castro, I.A., Effect of long-term ingestion of weakly oxidised flaxseed oil on biomarkers of oxidative stress in LDL-receptor knockout mice. Br. J. Nutr., 2016, 1–12.
25. [25] Firestone, D., Official Methods and Recommended Practices of the American Oil Chemists’ Society. fourth ed., 1997, American Oil Chemists’ Society, Champaign, IL.
26. [26] Oxidation in Omega-3 Oils: an Overview, 2015, A white paper prepared by the Global Organization for EPA and DHA Omega-3s and the Council for Responsible Nutrition Available at: http://crnusa.org/pdfs/GOED+CRNWhitePaper-Omega-3oxidation.pdf Accessed November 30, 2016.
27. [27] Davies, I.G., Graham, J.M., Griffin, B.A., Rapid separation of LDL subclasses by iodixanol gradient ultracentrifugation. Clin. Chem. 49 (2003), 1865–1872.
28. [28] Mak, I.T., Weglicki, W.B., Antioxidant activity of calcium channel blocking drugs. Methods Enzymol. 234 (1994), 620–630.
29. [29] Yagi, K., Assay for blood plasma or serum. Methods Enzymol. 105 (1984), 328–331.
30. [30] Albert, B.B., Cameron-Smith, D., Hofman, P.L., Cutfield, W.S., Oxidation of marine omega-3 supplements and human health. Biomed. Res. Int., 2013, 2013, 464921.
31. [31] Burger, J., Gochfeld, M., Perceptions of the risks and benefits of fish consumption: individual choices to reduce risk and increase health benefits. Environ. Res. 109 (2009), 343–349.
32. [32] Rauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., Gottwik, M., Steinbeck, G., Del, C.U., Sack, R., Worth, H., Katus, H., Spitzer, W., Sabin, G., Senges, J., OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122 (2010), 2152–2159.
33. [33] Kromhout, D., Giltay, E.J., Geleijnse, J.M., n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 363 (2010), 2015–2026.
34. [34] Investigators, ORIGIN Trial, n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med. 367 (2012), 309–318.
35. [35] The Risk and Prevention Study Collaborative Group, n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 368 (2013), 1800–1808.
36. [36] Qato, D.M., Wilder, J., Schumm, L.P., Gillet, V., Alexander, G.C., Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern. Med. 176 (2016), 473–482.
37. [37] Barnes, P.M., Bloom, B., Nahin, R.L., Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007., 2008, 1–23 National health statistics reports.
38. [38] Bailey, R.L., Gahche, J.J., Miller, P.E., Thomas, P.R., Dwyer, J.T., Why US adults use dietary supplements. JAMA Intern. Med. 173 (2013), 355–361.
39. [39] Clarke, T.C., Black, L.I., Stussman, B.J., Barnes, P.M., Nahin, R.L., Trends in the Use of Complementary Health Approaches Among Adults: United States, 2002-2012. 2015, 1–16 National health statistics reports.
40. [40] Backes, J., Melton, B., Ruisinger, J., Burkhardt, C., Moriarty, P., A comparison of patients’ prescribed, self-reported, and actual intake of supplemental EPA/DHA [abstract 161]. J. Clin. Lipidol. 10 (2016), 699–700.
41. [41] Hawkins, E.B., Ling, H., Burns, T.L., Hilleman, D.E., Perceptions, knowledge, and patterns of use of “fish oil” products in cardiac patients [abstract 23]. Pharmacotherapy, 32, 2012, e184.
42. [42] Stone, N.J., Robinson, J., Lichtenstein, A.H., Bairey Merz, C.N., Lloyd-Jones, D.M., Blum, C.B., McBride, P., Eckel, R.H., Schwartz, J.S., Goldberg, A.C., Shero, S.T., Gordon, D., Smith, S.C. Jr., Levy, D., Watson, K., Wilson, P.W., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a Report of the American College of cardiology/American heart association task force on practice guidelines. J. Am. Coll. Cardiol. 63 (2014), 2889–2934.
43. [43] Coon, S.A., Stevens, V.W., Brown, J.E., Wolff, S.E., Wrobel, M.J., Comparison of dietary supplement product knowledge and confidence between pharmacists and health food store employees. J. Am. Pharm. Assoc. 55:2003 (2015), 161–168.